Reminder: Ladenburg Thalmann to host virtual discussion June 22, 2023 at 1:00 PM EDT with Jaguar CEO and leading patient advocates on impact of cancer therapy-related diarrhea on patients & importance of the patient voice in supportive care; Click here to register for event

Jaguar recently completed patient enrollment in its ongoing pivotal, Phase 3 OnTarget clinical trial of crofelemer for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy with or without chemotherapy

SAN FRANCISCO, CA / ACCESSWIRE / June 15, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that at 6 p.m. EDT on Wednesday, June 21, 2023, Lisa Conte, Jaguar's president, founder, and CEO, will present virtually at the MedInvest Oncology Investor Conference and will be available to participate in virtual one-on-one meetings during the event.

Participation Instructions for Jaguar Presentation at MedInvest Oncology Investor Conference

When: Wednesday, June 21, 2023 at 6:00 p.m. Eastern Daylight Time

Link to view presentation: Click Here

Participation Instructions for Ladenburg Thalmann Virtual Discussion Event

Who: Event is exclusively for investors, financial analysts, business media, and business development executives.

When: Thursday, June 22, 2023 at 1:00 p.m. Eastern Daylight Time

Registration Link: Click Here

Jaguar recently completed patient enrollment in its ongoing pivotal, Phase 3 OnTarget clinical trial of crofelemer for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy with or without chemotherapy, and the primary endpoint based on patient reported outcomes is expected in October 2023. The OnTarget trial is evaluating the effectiveness of crofelemer's novel mechanism of action - the modulation of two gastrointestinal chloride ion channels - to mitigate or substantially reduce chronic cancer therapy-related diarrhea. Jaguar's expectation is that the global OnTarget trial will provide evidence that diarrhea associated with targeted cancer therapies is chronic, not acute, and impacts the patient's ability to perform activities of daily living as well as remain on their cancer therapy regimens at proven doses for better outcomes.

About Cancer Therapy-related Diarrhea

A significant proportion of patients undergoing cancer therapy experience diarrhea, and diarrhea has the potential to cause dehydration, potential infections, and non-adherence to treatment in this population. Novel "targeted cancer therapy" agents, such as epidermal growth factor receptor (EGFR) antibodies and tyrosine kinase inhibitors (TKIs), with or without cycle chemotherapy agents, may cause increased electrolyte and fluid content in the gut lumen, which results in passage of loose/watery stools (i.e., diarrhea). Diarrhea has been reported as one of the most common side effects of TKIs and may result in cancer therapy drug holidays or reductions from therapeutic dose, potentially impacting patient outcome. Diarrhea is also a common side effect of some approved CDK 4/6 inhibitors. Patients with CTD are 40% more likely to discontinue their chemotherapy or targeted therapy than patients without CTD,¹ and the cost of care of CTD patients is estimated to be 2.9 times higher than for patients who are not experiencing CTD.²

About Jaguar Health, Napo Therapeutics & Jaguar Animal Health

Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, plant-based, sustainably derived prescription medicines for people and animals with GI distress, including chronic, debilitating diarrhea. Our crofelemer drug product candidate is the subject of the OnTarget study, an ongoing pivotal Phase 3 clinical trial for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy. Jaguar Health is the majority shareholder of Napo Therapeutics S.p.A. (f/k/a Napo EU S.p.A.), an Italian corporation established by Jaguar Health in Milan, Italy in 2021 that focuses on expanding crofelemer access in Europe. Jaguar Animal Health is a tradename of Jaguar Health.

For more information about Jaguar Health, please visit https://jaguar.health. For more information about Napo Therapeutics, visit napotherapeutics.com.

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar's expectation that Company management will present at the 2023 MedInvest Oncology Investor Conference, the expectation that Ladenburg Thalmann will host a virtual discussion event June 22, 2023, the expectation that the primary endpoint of the OnTarget trial will be available in October 2023, and the expectation that the OnTarget trial will provide evidence that diarrhea associated with targeted cancer therapies is chronic, not acute, and impacts the patient's ability to perform activities of daily living as well as remain on their cancer therapy regimens at proven doses for better outcomes. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

¹ Pablo C. Okhuysen, M.D., The impact of cancer-related diarrhea on changes in cancer therapy patterns: Real world evidence

² Eric Roeland, M.D., FAAHPM, Healthcare utilization and costs associated with cancer-related diarrhea

CONTACT:

hello@jaguar.health
Jaguar-JAGX

SOURCE: Jaguar Health, Inc.